Cargando…

Safety of lung cancer surgery during COVID-19 in a pandemic epicenter

BACKGROUND: The influence of SARS-CoV-2 on surgery for non–small cell lung cancer needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. OBJECTIVE: This study reports on the 90-day rate of infection as well as the morbidity and mortality of lung surgery for...

Descripción completa

Detalles Bibliográficos
Autores principales: Villena-Vargas, Jonathan, Lutton, Evan M., Mynard, Nathan, Nasar, Abu, Voza, Francesca, Chow, Oliver, Lee, Benjamin, Harrison, Sebron, Stiles, Brendon M., Port, Jeffrey L., Altorki, Nasser K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by The American Association for Thoracic Surgery 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885108/
https://www.ncbi.nlm.nih.gov/pubmed/35459540
http://dx.doi.org/10.1016/j.jtcvs.2021.11.092
_version_ 1784660328381939712
author Villena-Vargas, Jonathan
Lutton, Evan M.
Mynard, Nathan
Nasar, Abu
Voza, Francesca
Chow, Oliver
Lee, Benjamin
Harrison, Sebron
Stiles, Brendon M.
Port, Jeffrey L.
Altorki, Nasser K.
author_facet Villena-Vargas, Jonathan
Lutton, Evan M.
Mynard, Nathan
Nasar, Abu
Voza, Francesca
Chow, Oliver
Lee, Benjamin
Harrison, Sebron
Stiles, Brendon M.
Port, Jeffrey L.
Altorki, Nasser K.
author_sort Villena-Vargas, Jonathan
collection PubMed
description BACKGROUND: The influence of SARS-CoV-2 on surgery for non–small cell lung cancer needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. OBJECTIVE: This study reports on the 90-day rate of infection as well as the morbidity and mortality of lung surgery for cancer in a tertiary care hospital located in a pandemic epicenter. METHODS: We conducted a retrospective review of a prospective database to identify consecutive patients who underwent lung cancer resection before (January 1, 2020-March 10, 2020, group 1; 57 patients) and during the COVID-19 pandemic (March 11, 2020-June 10, 2020, group 2; 41 patients). The primary end point was the occurrence of SARS-CoV-2 infection during the first 90-days after surgery. The secondary outcome measure was 90-day perioperative morbidity and mortality. RESULTS: Patient characteristics were not significantly different between the groups. Ninety-day COVID-19 infection rates was 7.3% (3 out of 41) for patients undergoing an operation during the pandemic and 3.5% (2 out of 57) in patients operated on immediately before the pandemic. All patients tested positive 10 to 62 days after the index surgical procedure following hospital discharge. Four COVID-19–positive patients were symptomatic and 4 out of 5 patients required hospitalization, were men, previous or current smokers with hyperlipidemia, and underwent a sublobar resection. Univariate analysis did not identify any differences in postoperative complications before or during the COVID-19 pandemic. Ninety-day mortality was 5% (2 out of 41) for lung cancer surgery performed during the pandemic, with all deaths occurring due to COVID-19, compared with 0% (0 out of 57) mortality in patients who underwent an operation before the pandemic. CONCLUSIONS: During the COVID-19 pandemic, COVID-19 infections occurred in 7.3% of patients who underwent surgery for non–small cell lung cancer. In this series all infections occurred after hospital discharge. Our results suggest that COVID-19 infections occurring within 90 days of surgery portend a 40% mortality, warranting close postoperative surveillance.
format Online
Article
Text
id pubmed-8885108
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher by The American Association for Thoracic Surgery
record_format MEDLINE/PubMed
spelling pubmed-88851082022-03-01 Safety of lung cancer surgery during COVID-19 in a pandemic epicenter Villena-Vargas, Jonathan Lutton, Evan M. Mynard, Nathan Nasar, Abu Voza, Francesca Chow, Oliver Lee, Benjamin Harrison, Sebron Stiles, Brendon M. Port, Jeffrey L. Altorki, Nasser K. J Thorac Cardiovasc Surg Thoracic: Lung Cancer BACKGROUND: The influence of SARS-CoV-2 on surgery for non–small cell lung cancer needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. OBJECTIVE: This study reports on the 90-day rate of infection as well as the morbidity and mortality of lung surgery for cancer in a tertiary care hospital located in a pandemic epicenter. METHODS: We conducted a retrospective review of a prospective database to identify consecutive patients who underwent lung cancer resection before (January 1, 2020-March 10, 2020, group 1; 57 patients) and during the COVID-19 pandemic (March 11, 2020-June 10, 2020, group 2; 41 patients). The primary end point was the occurrence of SARS-CoV-2 infection during the first 90-days after surgery. The secondary outcome measure was 90-day perioperative morbidity and mortality. RESULTS: Patient characteristics were not significantly different between the groups. Ninety-day COVID-19 infection rates was 7.3% (3 out of 41) for patients undergoing an operation during the pandemic and 3.5% (2 out of 57) in patients operated on immediately before the pandemic. All patients tested positive 10 to 62 days after the index surgical procedure following hospital discharge. Four COVID-19–positive patients were symptomatic and 4 out of 5 patients required hospitalization, were men, previous or current smokers with hyperlipidemia, and underwent a sublobar resection. Univariate analysis did not identify any differences in postoperative complications before or during the COVID-19 pandemic. Ninety-day mortality was 5% (2 out of 41) for lung cancer surgery performed during the pandemic, with all deaths occurring due to COVID-19, compared with 0% (0 out of 57) mortality in patients who underwent an operation before the pandemic. CONCLUSIONS: During the COVID-19 pandemic, COVID-19 infections occurred in 7.3% of patients who underwent surgery for non–small cell lung cancer. In this series all infections occurred after hospital discharge. Our results suggest that COVID-19 infections occurring within 90 days of surgery portend a 40% mortality, warranting close postoperative surveillance. by The American Association for Thoracic Surgery 2022-08 2022-03-01 /pmc/articles/PMC8885108/ /pubmed/35459540 http://dx.doi.org/10.1016/j.jtcvs.2021.11.092 Text en © 2022 by The American Association for Thoracic Surgery. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Thoracic: Lung Cancer
Villena-Vargas, Jonathan
Lutton, Evan M.
Mynard, Nathan
Nasar, Abu
Voza, Francesca
Chow, Oliver
Lee, Benjamin
Harrison, Sebron
Stiles, Brendon M.
Port, Jeffrey L.
Altorki, Nasser K.
Safety of lung cancer surgery during COVID-19 in a pandemic epicenter
title Safety of lung cancer surgery during COVID-19 in a pandemic epicenter
title_full Safety of lung cancer surgery during COVID-19 in a pandemic epicenter
title_fullStr Safety of lung cancer surgery during COVID-19 in a pandemic epicenter
title_full_unstemmed Safety of lung cancer surgery during COVID-19 in a pandemic epicenter
title_short Safety of lung cancer surgery during COVID-19 in a pandemic epicenter
title_sort safety of lung cancer surgery during covid-19 in a pandemic epicenter
topic Thoracic: Lung Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885108/
https://www.ncbi.nlm.nih.gov/pubmed/35459540
http://dx.doi.org/10.1016/j.jtcvs.2021.11.092
work_keys_str_mv AT villenavargasjonathan safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT luttonevanm safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT mynardnathan safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT nasarabu safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT vozafrancesca safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT chowoliver safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT leebenjamin safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT harrisonsebron safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT stilesbrendonm safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT portjeffreyl safetyoflungcancersurgeryduringcovid19inapandemicepicenter
AT altorkinasserk safetyoflungcancersurgeryduringcovid19inapandemicepicenter